Cargando…

A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus was first recognized in late 2019 and remains a significant threat. We therefore assessed the use of local methylene blue photodynamic viral inactivation (MB-PDI) in the oral and nasal cavities, in combination with the systemic anti-vira...

Descripción completa

Detalles Bibliográficos
Autores principales: Hepburn, Juliette, Williams-Lockhart, Susan, Bensadoun, René Jean, Hanna, Reem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686966/
https://www.ncbi.nlm.nih.gov/pubmed/36358582
http://dx.doi.org/10.3390/antiox11112211
_version_ 1784835886326743040
author Hepburn, Juliette
Williams-Lockhart, Susan
Bensadoun, René Jean
Hanna, Reem
author_facet Hepburn, Juliette
Williams-Lockhart, Susan
Bensadoun, René Jean
Hanna, Reem
author_sort Hepburn, Juliette
collection PubMed
description Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus was first recognized in late 2019 and remains a significant threat. We therefore assessed the use of local methylene blue photodynamic viral inactivation (MB-PDI) in the oral and nasal cavities, in combination with the systemic anti-viral, anti-inflammatory and antioxidant actions of orally ingested methylene blue (MB) and photobiomodulation (PBM) for COVID-19 disease. The proposed protocol leverages the separate and combined effects of MB and 660nm red light emitted diode (LED) to comprehensively address the pathophysiological sequelae of COVID-19. A total of eight pilot subjects with COVID-19 disease were treated in the Bahamas over the period June 2021–August 2021, using a remote care program that was developed for this purpose. Although not a pre-requisite for inclusion, none of the subjects had received any COVID-19 vaccination prior to commencing the study. Clinical outcome assessment tools included serial cycle threshold measurements as a surrogate estimate of viral load; serial online questionnaires to document symptom response and adverse effects; and a one-year follow-up survey to assess long-term outcomes. All subjects received MB-PDI to target the main sites of viral entry in the nose and mouth. This was the central component of the treatment protocol with the addition of orally ingested MB and/or PBM based on clinical requirements. The mucosal surfaces were irradiated with 660 nm LED in a continuous emission mode at energy density of 49 J/cm(2) for PDI and 4.9 J/cm(2) for PBM. Although our pilot subjects had significant co-morbidities, extremely high viral loads and moderately severe symptoms during the Delta phase of the pandemic, the response to treatment was highly encouraging. Rapid reductions in viral loads were observed and negative PCR tests were documented within a median of 4 days. These laboratory findings occurred in parallel with significant clinical improvement, mostly within 12–24 h of commencing the treatment protocol. There were no significant adverse effects and none of the subjects who completed the protocol required in-patient hospitalization. The outcomes were similarly encouraging at one-year follow-up with virtual absence of “long COVID” symptoms or of COVID-19 re-infection. Our results indicate that the protocols may be a safe and promising approach to challenging COVID-19 disease. Moreover, due its broad spectrum of activity, this approach has the potential to address the prevailing and future COVID-19 variants and other infections transmitted via the upper respiratory tract. Extensive studies with a large cohort are warranted to validate our results.
format Online
Article
Text
id pubmed-9686966
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96869662022-11-25 A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up Hepburn, Juliette Williams-Lockhart, Susan Bensadoun, René Jean Hanna, Reem Antioxidants (Basel) Article Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus was first recognized in late 2019 and remains a significant threat. We therefore assessed the use of local methylene blue photodynamic viral inactivation (MB-PDI) in the oral and nasal cavities, in combination with the systemic anti-viral, anti-inflammatory and antioxidant actions of orally ingested methylene blue (MB) and photobiomodulation (PBM) for COVID-19 disease. The proposed protocol leverages the separate and combined effects of MB and 660nm red light emitted diode (LED) to comprehensively address the pathophysiological sequelae of COVID-19. A total of eight pilot subjects with COVID-19 disease were treated in the Bahamas over the period June 2021–August 2021, using a remote care program that was developed for this purpose. Although not a pre-requisite for inclusion, none of the subjects had received any COVID-19 vaccination prior to commencing the study. Clinical outcome assessment tools included serial cycle threshold measurements as a surrogate estimate of viral load; serial online questionnaires to document symptom response and adverse effects; and a one-year follow-up survey to assess long-term outcomes. All subjects received MB-PDI to target the main sites of viral entry in the nose and mouth. This was the central component of the treatment protocol with the addition of orally ingested MB and/or PBM based on clinical requirements. The mucosal surfaces were irradiated with 660 nm LED in a continuous emission mode at energy density of 49 J/cm(2) for PDI and 4.9 J/cm(2) for PBM. Although our pilot subjects had significant co-morbidities, extremely high viral loads and moderately severe symptoms during the Delta phase of the pandemic, the response to treatment was highly encouraging. Rapid reductions in viral loads were observed and negative PCR tests were documented within a median of 4 days. These laboratory findings occurred in parallel with significant clinical improvement, mostly within 12–24 h of commencing the treatment protocol. There were no significant adverse effects and none of the subjects who completed the protocol required in-patient hospitalization. The outcomes were similarly encouraging at one-year follow-up with virtual absence of “long COVID” symptoms or of COVID-19 re-infection. Our results indicate that the protocols may be a safe and promising approach to challenging COVID-19 disease. Moreover, due its broad spectrum of activity, this approach has the potential to address the prevailing and future COVID-19 variants and other infections transmitted via the upper respiratory tract. Extensive studies with a large cohort are warranted to validate our results. MDPI 2022-11-08 /pmc/articles/PMC9686966/ /pubmed/36358582 http://dx.doi.org/10.3390/antiox11112211 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hepburn, Juliette
Williams-Lockhart, Susan
Bensadoun, René Jean
Hanna, Reem
A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
title A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
title_full A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
title_fullStr A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
title_full_unstemmed A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
title_short A Novel Approach of Combining Methylene Blue Photodynamic Inactivation, Photobiomodulation and Oral Ingested Methylene Blue in COVID-19 Management: A Pilot Clinical Study with 12-Month Follow-Up
title_sort novel approach of combining methylene blue photodynamic inactivation, photobiomodulation and oral ingested methylene blue in covid-19 management: a pilot clinical study with 12-month follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686966/
https://www.ncbi.nlm.nih.gov/pubmed/36358582
http://dx.doi.org/10.3390/antiox11112211
work_keys_str_mv AT hepburnjuliette anovelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT williamslockhartsusan anovelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT bensadounrenejean anovelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT hannareem anovelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT hepburnjuliette novelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT williamslockhartsusan novelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT bensadounrenejean novelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup
AT hannareem novelapproachofcombiningmethylenebluephotodynamicinactivationphotobiomodulationandoralingestedmethyleneblueincovid19managementapilotclinicalstudywith12monthfollowup